510(k) device
Apyx
Escala Medical · Fixation, Non-Absorbable Or Absorbable, For Pelvic Use (PBQ, Class II) · First FDA decision Apr 5, 2022, newest Jul 25, 2023Pelvic organ prolapse
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
5
Naming "Apyx"
MAUDE reports
5
Brand "Apyx", since 2015
PubMed studies
16
Mentioning "Apyx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Apyx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Apyx510(k)
K230730 · Decided Jul 25, 2023 · 131 days after receipt
Device type: Fixation, Non-Absorbable Or Absorbable, For Pelvic Use (PBQ) · Obstetrics & Gynecology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Apyx", any status and sponsor, newest update first.
Apyx MedicalNot on our public-company list
NCT06243744 · 7 participants · Start Nov 30, 2023 · Primary completion Jul 10, 2025
Device: Renuvion APR System · For: Skin Laxity; Tissue Degeneration; Tissue Breakdown and 2 more
Sites: Bradenton, Florida; Sarasota, Florida
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Apyx", and for the whole product code for context.
This brand
5 reports: 0 malfunction, 5 injury, 0 death
Whole product code PBQ
65 reports: 48 malfunction, 16 injury, 0 death
Newest reports for this brand
- APYX RENUVIONInjury
MW5185757 · Received Mar 25, 2026 · Event dated Mar 11, 2026
Device type: Electrosurgical, Cutting & Coagulation & Accessories (GEI)
Patient problem as coded: Pneumothorax
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Apyx"[tiab]. The summary above synthesizes these.
- Novel Incision-free Device for Transvaginal Apical Pelvic Organ Prolapse Repair.
Nathan JH, Goldberg RP, Chill HH, et al. · J Minim Invasive Gynecol · 2020Evaluation Study, Research Support, Non-U.S. Gov't
- Safety of Helium-based Plasma Technology for Coagulation of Soft Tissue: A Retrospective Review.
Shridharani SM, Kennedy ML · Aesthet Surg J Open Forum · 2022
- Biomedical application of cold plasma: navigating through plasma types and devices by antimicrobial effectiveness and tissue tolerance.
Thompson TP, Connelly A, Kelly S, et al. · Adv Ther (Weinh) · 2025
- Helium Plasma-Driven Radiofrequency for Skin Contraction: Clinical Use, Safety Recommendations, and Results in High-Definition Body Contouring Surgery.
Hoyos AE, Perez ME, Cala LC, et al. · Aesthet Surg J Open Forum · 2025
- Helium Plasma-Assisted Breast Reduction: A Pilot Study.
Moncada S, Nichols C · Aesthet Surg J Open Forum · 2022
- Enhanced Cytotoxic Effects of Cold Plasma Deposition of Topotecan: A Novel Approach for Local Cancer Drug Delivery to Glioblastoma Cells.
Pinheiro Lopes B, O'Neill L, Bourke P, et al. · Cancers (Basel) · 2025
- Renuvion/J-Plasma for Subdermal Skin Tightening Facial Contouring and Skin Rejuvenation of the Face and Neck.
Gentile RD · Facial Plast Surg Clin North Am · 2019Review
- Expansion of Renuvion Application to Areas Beyond the Submental Region: Review and Experience.
Driscoll CR, Davidson AL, Marturano MN, et al. · Aesthet Surg J Open Forum · 2024
- Evaluating the Healing Potential of J-Plasma Scalpel-Created Surgical Incisions in Porcine and Rat Models.
Elmore L, Minissale NJ, Israel L, et al. · Biomedicines · 2024
- Tissue Contraction With Helium-Based Plasma Radiofrequency Technology: A Preliminary Report of Initial Ultrasound Findings.
Nichols C, Albershardt D · Aesthet Surg J Open Forum · 2024Case Reports
- A Single-site Postmarket Retrospective Chart Review of Subdermal Coagulation Procedures with Renuvion.
Doolabh V · Plast Reconstr Surg Glob Open · 2019
- Helium Plasma Radiofrequency Brow Lift: Description of a Novel Technique and Retrospective Study on Safety, Efficacy, and Durability.
Lacerna Kimbrell M · Aesthet Surg J Open Forum · 2025Case Reports
Other devices of this type
Also filed under product code PBQ.
- MenditEscala Medical, Ltd. · 510(k) 2026
- Saffron Fixation SystemColoplast A/S · 510(k) 2022
- NeuGuidePop Medical Solutions · 510(k) 2016
- Endofast Reliant Scp, Endofast Reliant LapIbi Israel Biomedical Innovations , Ltd. · 510(k) 2013
- AnchorsureNeomedic International S.L. · 510(k) 2012
- Gynecare Prolene Fastener SystemETHICON, Inc. · 510(k) 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.